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Psoralea corylifolia L. (Fabaceae) is a widely used medical plant in China. This study was designed to screen and identify bioactive
compounds with anticancer activity from the seeds of Psoralea corylifolia L. One volatile fraction (fraction I) and three other
fractions (fraction II, III, IV) from methanol extraction of P. corylifolia L. were obtained. Bioactivities of these fractions were
evaluated by the cytotoxicity on KB, KBv200, K562, K562/ADM cancer cells with MTT assay. Major components in the active
fraction were identiﬁed by HPLC/MSn. Fraction IV signiﬁcantly inhibits the growth of cancer cells in a dose-dependent manner.
The IC50 values were 21.6, 24.4, 10.0 and 26.9, respectively. Psoralen and isopsoralen, isolated from fraction IV, were subject to
bioactive assay and presented a dose-dependent anticancer activity in four cancer cell lines (KB, KBv200, K562 and K562/ADM).
The IC50 values of psoralen were 88.1, 86.6, 24.4 and 62.6, which of isopsoralen were 61.9, 49.4, 49.6 and 72.0, respectively.
Apoptosis of tumor cell signiﬁcantly increased after treated with psoralen and isopsoralen. Induction of apoptotic activity was
conﬁrmed by ﬂow cytometry after staining with Annexin V/PI. These results suggested psoralen and isopsoralen contribute to
anticancer eﬀect of P. corylifolia L.
1.Introduction
The seeds of Psoralea corylifolia L. (Fabaceae), well-known
as traditional Chinese medicine “Buguzhi”, are widely used
for the treatment of various kinds of disorders such as
asthma, cough, nephritis, vitiligo and calvities [1, 2]. The
constituentsinP.corylifolia L.includecoumarins andﬂavone
components, such as psoralen, isopsoralen, psoralidin,
neobavaisoﬂavone, bavachin, corylin, bavachalcone, and so
forth [3]. It has been reported that the methanol (MeOH)
extract of P. corylifolia L. showed remarkable inhibitory
eﬀects on NO production [4]. The cytotoxic, anticancer and
immunomodulatory properties of P. corylifolia L. seeds have
already been reported [5]. In addition, the active fraction
from both roots and seeds of P. corylifolia L. exhibited
cytotoxicity against cultured human cancer cell lines [6,
7]. However, to the best of our knowledge, the bioactive
compounds from the seed of P. corylifolia L., which are
potential to inhibit cancer cell proliferation in vitro,h a v en o t
yet been evaluated.
The aim of the present study was to screen and identify
active compounds with anticancer eﬀect from the seeds of
P. corylifolia L. Bioassay-guided isolation was performed to
obtain two active compounds from MeOH extracts of P.
corylifolia L. seeds. Psoralen and isopsoralen exhibited dose-
dependent anticancer eﬀect on four (KB, KBv200, K562,
K562/ADM) cell lines.
2.Methods
2.1. Plant Materials and Reagents. The crude material of P.
corylifolia L. seed was purchased from Hangzhou Traditional
Chinese Medicine Company (Hangzhou, China). The crude
sample was authenticated morphologically by Prof. He Qing
(College of Pharmaceutical Sciences, Zhejiang University).
A voucher specimen was deposited in the herbaria (Depart-
ment of Chinese Medicine Sciences & Engineering, Zhejiang
University, China), under the acquisition number of GZ.
Standards of psoralen and isopsoralen were purchased from
National Institute for the Control of Pharmaceutical and
Biological Products (Beijing, China).
MeOH and EtOH were analytical grade from Hangzhou
Reagent Company (Hangzhou, China). HPLC-grade ace-
tonitrile and DMSO were from E. Merck (Darmstadt,
Germany). Distilled water used in all experiments was2 Evidence-Based Complementary and Alternative Medicine
puriﬁed by a Milli-Q system (Milford, MA, USA). DMEM,
RPMI-1640 medium, fetal bovine serum and non-essential
amino acids were purchase from Gibco (CA, USA). Trypsin
was obtained from Sigma (St Louis, USA). Newborn calf
serumwaspurchased fromSeRaBiotechCo.Ltd(Hangzhou,
China).
Vincristine sulfate (Hanye Pharmaceutical Co. Ltd,
Guangzhou, China) and doxorubicin hydrochloride (Haiz-
heng Hisun Pharmaceutical Co. Ltd, Zhejiang, China) were
used as positive control.
2.2.ExtractionandIsolation. Air-dried plantmaterial (500g)
was powdered and macerated with 2L distilled water
overnight. The solution was Soxhlet’s extracted for 5h to
obtain volatile components as fraction I. The ﬁltered deposit
was extracted with 2L 95% EtOH solution for 2h. The
extraction was ﬁltrated and evaporated at 60◦C in vacuum.
The extract was subjected to an ODS-C18 columnfor further
separation with a step gradient of MeOH aqueous solution.
The elution of 30, 50, and 70% methanol was collected to
obtain fraction II, III, and IV.
Further separations of fraction IV were performed on a
RP-18 semi-preparative column (5μm, 10mm i.d. × 25cm;
Hanbang Science & Technology Co., Jiangsu, China) and
Agilent 1100 series preparative HPLC system (Waldbronn,
Germany) equipped with a binary high-pressure mixing
pump and fraction collector.
2.3. Cell Culture. Human oral carcinoma line KB, KBv200
(the vincristine resistance subline of KB), human ery-
throleukemia cell K562 and K562/ADM (the doxorubicin
resistance subline of K562) were kindly gifted by Prof. Yang
Bo(College ofPharmaceutical Science,Zhejiang University),
and human periodontal ligament (HPDL) cell were gifted
by Prof. Hua Fu (College of Medicine, Zhejiang University).
K562and K562/ADMwere cultured inRPMI-1640 medium,
whilst KB and KBv200 were in DMEM; supplemented with
10% heat-inactivated newborn calf serum and 1% non-
essential amino acids; HPDL cells were cultured in DMEM,
supplementedwith 10% heat-inactivated fetal bovine serum,
all with 100UmL−1 penicillin–streptomycin. All the cells
were incubated at 37◦C in a humidiﬁed atmosphere of 95%
air and 5% CO2 and passaged three times a week. After
passaged four times, HPDL cells could be used as normal
human cells.
2.4. Antitumor Activity Assays. The cytotoxity was ana-
lyzed by the 3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyl tetra-
zolium bromide (MTT) assay. In this assay, cancer cells
were seeded at cell density of 2 × 103 per well in 96-
well round-bottom test plate and incubated for 24h before
test. To examine the anticancer eﬀects of the P. corylifolia
L. fractions, the K562 and KB cells were incubated with
diﬀerent fractions (80μgm L −1). Each fraction was repeated
four times. Cells treated with 0.1% DMSO were included
as negative control. Vincristine sulfate and doxorubicin
hydrochloride, two clinically used anticancer drugs, were
used as positive control [8]. After 48-h incubation, 20μL
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Figure 1: Anticancer eﬀect of fractions I, II, III, and IV on KB
and K562 cell lines. The cells were incubated with vincristine
sulfate (VCR) or doxorubicin hydrochloride (Dox) or other test
compounds for 48h. Incubation with DMSO alone as control and
the ﬁnal concentration of DMSO in the medium never exceeded
0.1%. After 48h, the MTT assay was performed to measure cell
inhibition rate. Results were reported as mean (n = 4) percent of
untreated control with error bars showing the standard deviation.
Asterisks indicate signiﬁcant cytotoxicity relative to the positive
control (∗P < .05, ∗∗P < .01).
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Figure 2: Anticancer activity of fraction IV on diﬀerent cell lines.
Results were expressed as means ± SD of four separate experiments
for each data point.
MTT solution (5mg mL−1) was added to each well and
incubated at 37◦C for 4h. After removing the medium, the
formazan was dissolved in DMSO and the optical density
was measured at 550nm using an ELx800 UV universal
microplate reader (Bio-Tek, USA). The inhibition rate was
calculated using [1]:
InhibitionRate =
1 − (Sample OD − BlankOD)
(Control OD −BlankOD)
. (1)Evidence-Based Complementary and Alternative Medicine 3
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Figure3:HPLCchromatogramofthePsoraleacorylifoliaL.fraction
IV,detection wavelength300nm.Peaksaredescribed inthetext and
putative identiﬁcations are given in Table 1.
Similarly, anticancer eﬀect of fraction IV, psoralen and
isopsoralen was assayed on K562, K562/ADM, KB, KBv200,
and HPDL cells by the MTT assay. IC50 was calculated from
dose-inhibition curves.
3.IdentiﬁcationofActive
CompoundsinFractionIV
Preliminary phytochemical investigations of the fractions
were carried out by HPLC/MSn. The chromatographic sep-
aration was performed on a Agilent Zorbax SB-C18 column
(5μm, 4.6mm i.d. × 25cm, Hanbang Science & Technology
Co., Jiangsu, China) with an Agilent 1100 HPLC system
(Waldbroonn, Germany) equipped with a quaternary pump,
vacuumdegasser, autosampler, diode-array detector, column
heater-cooler and ChemStation system. A LCQ DECA XP
Plus mass spectrometer (Thermo Finnigan, San Jose, USA)
equippedwith an ESIinterface and an ion trap mass analyzer
were used to carry out the MS and MSn.T h em o b i l ep h a s e
consisted of two eluents: water (W) and acetonitrile (A).
The ﬂow rate was set at 0.8mL min−1 and the following
gradient was used: initial 75% W and 25% A; 25-min linear
change to 65% W and 35% A; 25-min linear to 50% W
and 50% A; 10-min linear to 30% W and 70% A. The
column temperature was set at 30◦C. UV detection was set
at 300nm and spectrograms were recorded between 190
and 400nm at the apex of each peak. By comparison of
molecular weight, retention time, UV absorbance and mass
fragments information with those of published data and
the standards, a number of compounds were tentatively
identiﬁed.
3.1. Morphological Studies of Apoptotic Cell. KB cells from
exponentially growing cultures were seeded within 96-well
microplate and incubated for 24h. Then cells were treated
with vincristine sulfate, psoralen or isopsoralen and for 48h.
After treatment, cells were washed with PBS once. Cells
were investigated using phase contrast microscope (Leika
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Figure 4: The inhibition ability of psoralen (a) and isopsoralen
(b) on proliferation of four tumor cells. The cells were incubated
with vincristine sulfate or doxorubicin hydrochloride and diﬀerent
concentrations of psoralen and isopsoralen for 48h. Incubation
with DMSO alone as control and the ﬁnal concentration of DMSO
in the medium never exceeded 0.1%. After 48h, the MTT assay
wasperformed to measure cell inhibitionrate. Results are expressed
as means ± SD of four separate experiments for each data point.
Signiﬁcantdiﬀerence was set at .95.
DMI6000, USA). And then cells were stained with Hoechst
33342 dye assay (BeyotimeInst. Biotech.)for 15min at room
temperature before examining under a ﬂuorescent micro-
scope (Leika DMI6000, USA) with an excitation wavelength
of 365nm [9].
3.2. Detection of Apoptosis by Annexin V-EGFP/PI Staining.
KB cells (5 × 105) were seeded within 6-well plate and
incubated for 24h before treated with vincristine sulfate,4 Evidence-Based Complementary and Alternative Medicine
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Figure 5: The inhibition ability of psoralen and isopsoralen
on proliferation of HPDL cells. The cells were incubated with
doxorubicinhydrochloride anddiﬀerent concentrationsofpsoralen
and isopsoralen for 48 h. Incubation with DMSO alone as control
and the ﬁnal concentration of DMSO in the medium never
exceeded 0.1%. After 48h, the MTT assay was performed to
measure cell inhibition rate. Results are expressed as means ± SD
of four separate experiments for each data point.
psoralen or isopsoralen and for 48h. After treatment cells
were harvested by 0.25% (w/v) Trypsin-0.53mM EDTA
solution. The detection of apoptosis was measured with the
Annexin V-FITCApoptosisDetectionKitI(BDBiosciences).
Speciﬁc binding of Annexin V-FITC was performed by
the incubation of cells for 15min at room temperature in
the dark, in a binding buﬀer (10mM Hepes/NaOH (pH
7.4), 140mM NaCl, 2.5mM CaCl2) containing a saturat-
ing concentration of annexin V-ﬂuorescein isothiocyanate
(FITC) and propidium iodide (PI) [9, 10]. After incubation,
the cells were pelleted and analyzed in FACSCalibur Flow
Cytometer (BD Bioscience, USA). Annexin V+/PI− (lower
right) cells were recognized as apoptotic cells, while Annexin
V+/PI+ (upper right) cells were deﬁned as necrotic (or late
apoptotic). The data were analyzed using FACSComp5.2.1
Analysis Software (Becton-Dickinson Company, USA). Sim-
ilar tests were performed on K562 cells after 48h treatment
and on KB after 72h treatment.
3.3. Statistics. All data were expressed as mean ± SDStudent
t-test was used to compare the data of control group with
treated group. The condition of P < .05 was considered to be
statistically signiﬁcant.
4.Results
4.1. Anticancer Activity of the Isolated Fractions. The aim of
an anticancer agent is to trigger the apoptosis signaling sys-
tem in these cancer cells whilst disturbing their proliferation
[11, 12]. Many in vitro human cancer cells models, including
K562 [1]a n dK B[ 13], have been used to screen herbal
extracts for anticancer activity.
In the present work, the anticancer activity of fraction
I, II, III, and IV was assessed using the MTT assay on the
human oral carcinoma line KB and human erythroleukemia
cell K562. The results were exhibited as the inhibition
rate for each fraction tested on KB and K562 cell lines
(Figure 1). Fractions I, II, and III just displayed a weak
cytotoxicity on KB cells. Fraction I and III showed moderate
inhibition eﬀect on K562 cells, while fraction II did not
inhibit the growth of K562 cells. However, fraction IV
showed signiﬁcant cytotoxicity on the cancer cells after 48-h
exposure, inhibition rate was above 90% of K562 and KB at
80μgm L −1. The positive cytotoxic control agent, vincristine
sulfate (2 × 10−4 M) and doxorubicin hydrochloride (1.4 ×
10−5 M), can cause signiﬁcant cytotoxicity at the very low
concentration. The inhibition rate of fraction IV was above
80% compared with control groups and was in a dose-
dependent manner in a range of 5–80μgm L −1 (Figure 2). It,
therefore, suggests that fraction IV is a promising candidate
for further investigation.
4.2. Identiﬁcation of Active Compounds in Fraction IV. To
screen bioactive compounds from fraction IV, HPLC-API-
MSn was employed to identify the components. Figure 3
showed the analytical result of the chromatographic separa-
tion. Molecular weights of four major peaks were obtained.
By comparing API-MSn data, coupled with ultraviolet
absorption, HPLC retention time with data from [3, 13,
14], four possible structures of these compounds were
dereplicated. The positive ionization mode was used, so
most of the m/z data are [M + H]+. In this ionization
mode,wecandeducewhetherthesubstancehaveisopentenyl
from the m/z data [M-55]+, because ﬂavones and coumarin
combined with isopentenyl would lose this group and
indicate such m/z data. Because most of ﬂavones and
coumarins have a keto carbonyl group, their m/z data are
often characterized by [M–C4H7]+ and [M + H–CO]+,t h e r e
would be some [M-55]+, [M + H-28]+ and [M-55-28]+
fragments [3]. The detailed data of each peak are listed in
Table 1.
4.3. Dose-Dependent Anticancer Activity of Psoralen and
Isopsoralen. The major eﬀective components of this herb are
coumarins, in which psoralen and isopsoralen are two major
compounds. Pharmacological test revealed that psoralen
and isopsoralen have anticancer [15], immunomodulatory
[7], antibacterial and antivirus properties [2, 15]. Psoralen
derivatives are also active in vitro against human melanoma
cell line [16]( Figure 4).
In this study, psoralen and isopsoralen were isolated
after puriﬁcation, and the anticancer eﬀects of them on
four cell lines were studied. The inhibition rate of psoralen
and isopsoralen showed a concentration-dependent manner
(Figure 5). IC50 (drug concentration resulting in a 50%
inhibition of cell growth) value of fraction IV, psoralen and
isopsoralen is listed in Table 2.Evidence-Based Complementary and Alternative Medicine 5
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Figure 6: Microscopic analysis of the cytotoxic eﬀects of psoralen and isopsoralen. A group of cells undergoing cell death was examined by
ﬂuorescence microscopy after 48h treatment. After 48h of exposure, the nucleus of KB cells as well as the cell membrane appears to shrink
(green arrows) and the chromatin appears brighter due to condensation (white arrows). Besides membrane blebbing is apparent and the
nuclear architecture is rougher in appearance. (a and d): Untreated control KB cells; (b and e): 50μgm L −1 psoralen-treated KB cells; (c and
f):50μgm L −1 isopsoralen-treated KB cells.
Table 1: Putative identiﬁcation of main components of Psoralea corylifolia L. fraction IV.
Peak No.a Mass data UV (nm) Identiﬁcation
1 187 [M + H]+ 212.0, 240.0, 296.0, 326.0 Psoralenb
2 187 [M + H]+ 204.0, 244.0, 300.0 Isopsoralenb
3 323 [M + H]+, 267 [M–C4H7]+, 239 [M–C4H7–CO]+ 208.0, 248.0 Neobavaisoﬂavone
4 321 [M + H]+ 248.0, 300.0 Corylin
aPeaks No. refers to Figure 3;
bIdentiﬁcation throguh comparison the retention time with that of standard substance.
Table 2: Cytotoxic activity of fraction IV, psoralen and isopsoralenagainst cancer cell lines.
Cell line
KB KBv200 K562 K562/ADM
IC50 (μg/mL) IC50 (μg/mL) RFa IC50 (μg/mL) IC50 (μg/mL) RFa
Psoralea corylifolia L. fraction IV 21.60 24.40 1.13 10.00 26.90 2.69
Psoralen 88.10 86.60 0.98 24.40 62.60 2.57
Isopsoralen 61.90 49.40 0.80 49.60 72.00 1.45
aResistance factor (RF) was calculated as RF = IC50(R)/IC50(S); S, sensitive cell lines (KB, K562), R, multidrug-resistant cell lines (KBv200, K562/ADM),
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4.4. Eﬀects of Psoralen and Isopsoralen on Cancer Cell Apop-
tosis. The morphological examinations of the KB cells were
illustrated using phase contrast microscope and ﬂuorescence
microscopy (Figure 6). The control group cells showed a
typical polygonal and cobblestone monolayer appearance
(Figure 6(a)). Signiﬁcant decrease of the number of KB
cells treated with psoralen (50μgmL −1)o ri s o p s o r a l e n
(50μgmL −1) for 48h was observed compared with the
control group. Furthermore, the cell, treated with psoralen
and isopsoralen for 48h began to have morphological
changes, showing round-shaped cells poorly adhered to the
cultureﬂasks (Figures6(b)and 6(c)). The changes ofnuclear
morphology of KB with psoralen or isopsoralen treatment
for 48h were analyzed under a ﬂuorescence microscope
by Hoechst-staining (Figures 6(d)–6(f)). The nuclei of
the treated cells have nuclear shrinkage and condensed
chromatin.
Based on the morphological changes of KB cells after
treated by psoralen or isopsoralen for 48 and 72h, we further
veriﬁed the occurrence of psoralen and isopsoralen induced
apoptosis by Annexin V-PI staining methods. The results
showed that the proportion of apoptotic cells (lower right)
signiﬁcant elevated in isopsoralen (50μgmL −1)-treated KB
cells from 7.52% in untreated cells to 15.16%, while the
psoralen (50μgmL −1)-treatment increased the apoptotic
ratio to 9.30%. The psoralen and isopsoralen consider-
ably elevated the proportion of apoptotic cells after 48h
treatment. However, there was no signiﬁcant eﬀect after
72h treatment. And there is no diﬀerence or even a slight
decrease of necrotic cells (upper right) in KB cells after
treated with psoralen and isopsoralen for 48h. These results
suggested that apoptosis but not necrosis contributed to
the psoralen- and isopsoralen-induced death of KB cells.
Similarly, the proportion of apoptotic cells elevated in
isopsoralen (50μgmL −1)-treated K562 cells from 6.19% in
untreated cells to 14.28%, while the psoralen (50μgmL −1)-
treatment increased the apoptotic ratio to 9.87%.
5.Discussionand Conclusion
One important source of newer chemotherapeutic agents
is those chemicals derived from herbal sources. A num-
ber of phytochemicals have been demonstrated to possess
anticancer eﬀects [17]. The use of complementary and
alternative medicine such as botanical extracts is becoming
increasingly popular among cancer patients [18, 19].
In our study, we revealed for the ﬁrst time the potent
cytotoxicactions of P.corylifolia L. extract (fraction IV) using
two cancer cell lines and their corresponding multidrug-
resistant (MDR) cell lines. Further analysis of theconstituent
reveals that psoralen and isopsoralen are two active con-
stituentsin the extract. Fraction IV, psoralen and isopsoralen
can inhibit the growth of K562 and K562/ADM at low
concentration. They can also inhibit the growth of normal
human primary cell HPDL, but the IC50 values were
higher than ones of tumor cell lines, which suggested these
two active components had potential selective cytotoxicity.
Speciﬁcally, psoralen inhibited the growth of KB, KBv200,
K562 and K562/ADM with maximum inhibition rate 62.3,
75.3, 92.4, and 76.6% at 80μgmL −1, respectively; and
isopsoralen exhibited a maximum inhibition 72.6, 75.6,71.6,
and 67.0% at the same concentration. It was interesting
to ﬁnd that the IC50 value of fraction IV was lower than
both psoralen and isopsoralen. One plausible explanation
is that psoralen and isopsoralen have a synergic cytotoxic
eﬀect toward cancer cells. Or there may be other active
constituents, which possess a stronger eﬃcacy against cancer
cells in fraction IV. A predominant property is that fraction
IV, psoralen and isopsoralen do not show signiﬁcant cross
resistance in the MDR cell line KBv200 and K562/ADM.
Resistance factor [20] of fraction IV, psoralen and isopso-
ralen is 1.13, 0.98, and 0.80 on KBv200, respectively, and
2.69, 2.57 and 1.45 on K562/ADM. This indicates they may
be poor substrates for multidrug resistance transporters, for
example, P-gp, MRP, in cancer [20, 21] and can circumvent
the MDR mechanism in curing cancer.
The pharmacological mechanism of the anticancer activ-
ity of P. corylifolia L. extract, psoralen and isopsoralen is
still not fully understood. Previously psoralen had been
reported to destroy the mitochondria, and decrease the
energy supply for cancer cells and inhibiting the synthesis of
nucleic acid and protein [15]. Nicoletta et al. [22]r e p o r t e d
that psoralens have been proposed and used for psoriasis,
vitiligo and mycosis fungoides (T-cell lymphoma). Our
study showed that psoralen and isopsoralen induced cancer
cell apoptosis. Cell apoptosis is mediated by many factors.
P53 is a transcription factor at the pivot of a number of
pathways that mediate apoptosis in response to a variety of
cellular stresses [23]. The diﬀerences of apoptotic response
to psoralen and isopsoralen may provide some information
such as whether or not the induction of apoptosis of P.
corylifolia L. extract is dependent on p53.
In summary, analytical and pharmacological data
obtained from this study suggest that P. corylifolia L. signif-
icantly inhibits proliferation of sensitive and MDR cancer
cells in vitro, psoralen and isopsoralen are responsible for the
anticancer activity. The mechanism of apoptosis induction
and the synergic cytotoxic eﬀect will be the focus of future
studies, because the seed of P. corylifolia L. is a commonly
used botanical medicine.
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